• PRO
  • Events
  • About Blog Popular
  • Login
  • Register
  • PRO
  • Resources
    • Latest updates
    • Q&A
    • In-depth
    • In-house view
    • Practical resources
    • FromCounsel New
    • Commentary
  • Resources
  • Research
    • Legal research hub
    • Primary sources
    • Scanner: regulatory tracking
    • Lexy: powerful AI search
    • Research reports
    • Explore all
  • Research
  • Learn
    • All
    • Webinars
    • Videos
  • Learn
  • Experts
    • Find experts
    • Influencers
    • Client Choice New
    • Firms
    • About
    Introducing Instruct Counsel
    The next generation search tool for finding the right lawyer for you.
  • Experts
  • My newsfeed
  • Events
  • About
  • Blog
  • Popular
  • Legal research hub
  • Primary sources
  • Scanner: regulatory tracking
  • Lexy: powerful AI search
  • Research reports
  • Explore all
  • Find experts
  • Influencers
  • Client Choice New
  • Firms
  • About
Introducing Instruct Counsel
The next generation search tool for finding the right lawyer for you.
  • Compare
  • Topics
  • Interviews
  • Guides

Analytics

Review your content's performance and reach.

  • Analytics dashboard
  • Top articles
  • Top authors
  • Who's reading?

Content Development

Become your target audience’s go-to resource for today’s hottest topics.

  • Trending Topics
  • Discover Content
  • Horizons
  • Ideation

Client Intelligence

Understand your clients’ strategies and the most pressing issues they are facing.

  • Track Sectors
  • Track Clients
  • Mandates
  • Discover Companies
  • Reports Centre

Competitor Intelligence

Keep a step ahead of your key competitors and benchmark against them.

  • Benchmarking
  • Competitor Mandates
Home

Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Register now for your free, tailored, daily legal newsfeed service.

Questions? Please contact [email protected]

Register

Significant Changes by the VA in Country of Origin Requirements for Federal Supply Schedule Contracts

Sidley Austin LLP

To view this article you need a PDF viewer such as Adobe Reader. Download Adobe Acrobat Reader

If you can't read this PDF, you can view its text here. Go back to the PDF .

USA May 3 2016

Recently, the Department of Veterans Affairs (VA) published a significant change of policy with respect to VA Federal Supply Schedule (FSS) contracts that could have an immediate effect on pharmaceutical manufacturers. The announcement broadens mandatory VA Schedule 65 I B coverage to drugs that were previously excluded from that Schedule because of their non-compliance with the country-of-origin requirements of the Trade Agreements Act (TAA). 19 U.S.C. 2501 et seq. 

Until this change in policy, there was a contradiction between the requirement that all “covered drugs,” as referenced in the VA Master Agreement, be “made available for procurement under the FSS” and the exclusion from the FSS of covered drugs manufactured or “substantially transformed” in a “non-designated country” under the TAA; for example, covered drugs manufactured or “substantially transformed” in China, India or Malaysia could not be made available to U.S. government customers under the FSS. Now, the VA is requiring that “all covered drugs, regardless of country of substantial transformation, be available on a 65 I B FSS contract,” which means the VA will now require the listing of covered drugs that had been excluded due to TAA restrictions. 

Background on TAA

Contracts that are subject to the TAA, which includes all FSS contracts, incorporate the applicable Federal Acquisition Regulation (FAR) Trade Agreements Act clause, which essentially requires that government customers purchase only U.S. or designated country end products. See, e.g., FAR Subpart 25.4; FAR 52.225-5. Designated countries include those that have entered bilateral or multilateral free trade agreements with the U.S., least developed countries, Caribbean Basin countries and countries that are signatories to the World Trade Organization’s Government Procurement Agreement. See FAR 25.003. While the applicable regulations allow for non-availability exceptions to the requirements if a particular end product is not manufactured in the U.S. or a designated country in a sufficient quantity to fulfill the requirements, before this announced policy change, the VA did not enable such non-availability determinations. 

New VA Policy

Under the new policy, a Contracting Officer may make an individual non-availability determination for any covered drug that does not have a TAA-compliant country of origin as a result of information provided by the manufacturer or distributor that neither the offered end product nor similar or like items are mined, produced or manufactured in the United States or a designated country in sufficient quantity to fulfill the requirements. The notice does not provide details of how such procedures will be conducted; however, very short deadlines were published for providing data and submitting contract modifications. 

Upcoming Deadlines 

This announcement provided very tight deadlines. First, by Tuesday April 26, just one week after the announcement, VA required that manufacturers submit Non-Federal Average Manufacturer Price data to the VA’s Office of Pharmacy Benefits Management Services for all of their TAA non-compliant covered drugs. 

Second, the announcement set a May 6 deadline for submission of either a Mass Modification by current FSS contractors, or a Request for Modification or Interim Agreement (IA) for manufacturers not currently holding FSS contracts, which would be the case for companies whose only covered drugs have been non-compliant with the TAA. 

Third, by June 6, all TAA non-compliant covered drugs must be on an FSS contract or covered by an IA.

Significance for Pharmaceutical Manufacturers

Although the VA did not provide many details in connection with this announcement, this change in policy has a number of significant implications. On the one hand, it provides an opportunity for pharmaceutical manufacturers to increase their sales through FSS contracts. Specifically, manufacturers that produce drugs in non-designated countries, such as China, India or Malaysia, will now have the U.S. government market available to them through the FSS program. On the other hand, the new policy mandates introduction into the U.S. government market via FSS contracts of competitor products that had been excluded; however, exactly how non-availability determinations will be made in this context has not been detailed.

Given the quick and demanding deadlines imposed by the VA, and the limited guidance provided in the announcement, it will likely prove challenging for manufacturers to meet the deadlines and implement the new requirements as the VA intends. 

Sidley Austin LLP - William A. Sarraille, Howard J. Stanislawski and Wandaly E. Fernandez

Back Forward
  • Save & file
  • View original
  • Forward
  • Share
    • Facebook
    • Twitter
    • Linked In
  • Follow
    Please login to follow content.
  • Like
  • Instruct

add to folder:

  • My saved (default)
  • Read later
Folders shared with you

Filed under

  • USA
  • Healthcare & Life Sciences
  • Product Regulation & Liability
  • Projects & Procurement
  • Sidley Austin LLP

Organisations

  • US Department of Veterans Affairs

Popular articles from this firm

  1. Second California Law Mandating Specific Number of Underrepresented Board Members Struck Down as Unconstitutional *
  2. SEC Brings First Enforcement Action Over ESG Disclosures *
  3. Data Matters: The Declaration for the Future of the Internet *
  4. What Fund Managers and Investors Should Know About the SEC’s Bold New Regulatory Agenda *
  5. Blockchain Tracing: The U.S. Government’s Newest Tool to Combat Foreign Crime *

If you would like to learn how Lexology can drive your content marketing strategy forward, please email [email protected].

Powered by Lexology

Related practical resources PRO

  • How-to guide How-to guide: How to avoid liability for defective products in supply of goods agreements (USA)
  • Checklist Checklist: FCPA due diligence of third-party intermediaries (USA)
  • How-to guide How-to guide: How to draft a confidentiality agreement (UK)

Related research hubs

  • USA
  • Projects & Procurement
  • Healthcare & Life Sciences
Back to Top
Resources
  • Daily newsfeed
  • Commentary
  • Q&A
  • Research hubs
  • Learn
  • In-depth
  • Lexy: AI search
Experts
  • Find experts
  • Legal Influencers
  • Firms
  • About Instruct Counsel
More
  • About us
  • Blog
  • Events
  • Popular
Legal
  • Terms of use
  • Cookies
  • Disclaimer
  • Privacy policy
Contact
  • Contact
  • RSS feeds
  • Submissions
 
  • Login
  • Register
  • Follow on Twitter
  • Follow on LinkedIn

© Copyright 2006 - 2022 Law Business Research

Law Business Research